The Filing Desk

Veracyte vs GeneDx

Veracyte VCYT · GeneDx WGS · Health Care Services

Veracyte reported revenue of $517 million in fiscal 2025, 1.2 times GeneDx's $428 million in fiscal 2025. Veracyte's revenue grew 16.0% in its latest year, and GeneDx's grew 40.0%. Veracyte had an operating margin of 11.2%, against -3.1% at GeneDx. Free cash flow was $127 million at Veracyte and $14 million at GeneDx.

Side by side

VeracyteGeneDx
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$517M$428M
Revenue growth16.0%40.0%
Revenue growth a year, last 5 years34.5%19.0%
Gross margin70.1%69.7%
Operating margin11.2%−3.1%
Net margin12.8%−4.9%
Free cash flow$127M$14M
Free cash flow margin24.5%3.3%
Return on capital6.1%−5.3%
Net debt to EBITDA−4.6x—
Dividends and buybacks$0M$0M
Change in diluted share count3.1%6.5%
Last close$24.33$52.37
P/E at the last close15.8×—
Insider trades, last 12 monthssold $19.2 millionbought $106.6 million, sold $21.5 million
Piotroski F-score6 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
VeracyteGeneDx
Operating margin
Percent of revenue
VeracyteGeneDx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
VeracyteGeneDx

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Veracyte and GeneDx pages.